Titan Mining Files Base Shelf Prospectus and Establishes ATM Program

(TSX:TI),(NYSE MKT:TII), GOUVERNEUR, N.Y., Jan. 29, 2026 (GLOBE NEWSWIRE) — Titan Mining Corporation (TSX:TI, NYSE-A:TII), (“Titan” or the “Company“) today announced that it has filed a base shelf prospectus in Canada dated January 27, 2026 (the “Canadian Base Prospectus“) and a registration statement on Form F-10 (File No. 333-292602) (the “Registration Statement“) in the United […]

Amplify ETFs Declares January Income Distributions for its Income ETFs

CHICAGO, Jan. 29, 2026 (GLOBE NEWSWIRE) — Amplify ETFs announces January income distributions for its income ETFs. ETF Name Ticker Amount per Share Ex-Date Record Date Payable Date Amplify Bitcoin Max Income Covered Call ETF BAGY $ 1.14120 1/29/26 1/29/26 1/30/26 Amplify Bitcoin 2% Monthly Option Income ETF BITY $ 0.80740 1/29/26 1/29/26 1/30/26 Amplify

Terrapin Beer Co. Turns Up the Volume with a New Brand Identity Rooted in Music, Art and Craft Beer Culture

(NASDAQ:TLRY),(TSX:TLRY), ATHENS, Ga., Jan. 29, 2026 (GLOBE NEWSWIRE) — Terrapin Beer Co. (Terrapin), a craft beer brand by Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), today announced a comprehensive brand refresh. The brand now features new visual interpretations and artist collaborations across packaging, logos, taglines, and more. These new features align seamlessly with its

Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference

(NasdaqGM:SKYE), SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today presented a poster titled “Investigating the Efficacy of Nimacimab Alone or in Combination with Tirzepatide, and as a Maintenance Therapy Post Tirzepatide

Chicago Atlantic Real Estate Finance Announces Tax Reporting Information for 2025 Distributions

(NasdaqGM:REFI), CHICAGO, Jan. 29, 2026 (GLOBE NEWSWIRE) — Chicago Atlantic Real Estate Finance, Inc. (NASDAQ: REFI) (“Chicago Atlantic” or the “Company”), a commercial mortgage real estate investment trust, today announced year-end tax reporting information for its 2025 distributions. Stockholders are urged to consult with their personal tax advisors as to their specific tax treatment. Chicago

Kirby Corporation Announces 2025 Fourth Quarter and Full Year Results

(NYSE:KEX), 2025 fourth quarter and full year earnings per share of $1.68 and $6.33, respectively Inland marine fourth quarter utilization improved throughout the quarter, averaging in the mid to high-80% range for the quarter with further improvement into the low 90% range already seen in the 2026 first quarter Steady market conditions in coastal marine

Coda Octopus Group Reports Fiscal 2025 Financial Results

(NASDAQ:CODA), ORLANDO, FL, Jan. 29, 2026 (GLOBE NEWSWIRE) — Coda Octopus Group, Inc. (“CODA” or the “Company”) (Nasdaq: CODA) a global market leader in real-time 4D/5D/6D imaging sonar technology and AI-enabled real-time subsea imaging and enhanced situational awareness for manned and autonomous platforms and advanced augmented diving technology, today reported its audited financial results for

New Jersey orders additional 375 Xcelsior(R) clean-diesel buses from New Flyer

(TSX:NFI),(OTC US:NFYEF),(Other OTC:NFYEF),(TSX:NFI-DB),(TSX:NFI.DB), ST. CLOUD, Minn., Jan. 29, 2026 (GLOBE NEWSWIRE) — (TSX: NFI, OTC: NFYEF, TSX: NFI.DB) NFI Group Inc. (NFI), a leader in bus and coach mobility solutions, and subsidiary New Flyer of America Inc. (New Flyer), has received an additional order from New Jersey Transit Corporation (NJ TRANSIT) for 375 Xcelsior(R) 40-foot,

Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader

(NasdaqGM:KYMR), Data from the BREADTH Phase 2b asthma trial is expected to be reported in late-2027 Data from the ongoing parallel BROADEN2 Phase 2b atopic dermatitis trial is expected to be reported by mid-2027 WATERTOWN, Mass., Jan. 29, 2026 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class

Nobel Closes Non-Brokered Private Placement Offering

(TSX-V:NBLC),(OTC US:NBTRF),(Other OTC:NBTRF), THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. TORONTO, Jan. 29, 2026 (GLOBE NEWSWIRE) — Nobel Resources Corp. (TSX-V: NBLC; OTCPK: NBTRF) (the “Company” or “Nobel“) announces that it has closed, on

Scroll to Top